Holen Sie sich die Stockscreener-App
3.91
37.04%
-2.30
Aquestive Therapeutics Inc Aktie (AQST) Neueste Nachrichten
Why Aquestive Therapeutics (AQST) Is Down 39.4% After FDA Flags Deficiencies In Anaphylm Application – And What's Next - Yahoo Finance
A Look At Aquestive Therapeutics (AQST) Valuation After Anaphylm Regulatory Update And FDA Feedback - simplywall.st
Benzinga Bulls And Bears: Chevron, Palantir, Aquestive — And Real Estate Stocks Plummet - Benzinga
Oklo, Applied Digital, Opendoor Technologies, Vistra, Aquestive Therapeutics: Stocks making the biggest moves today - MSN
Aquestive Therapeutics Inc. (AQST) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
AQST Stock Plunges On An FDA Setback For Its Allergy Drug – Here’s What Has Changed - Stocktwits
Sector Update: Health Care - MarketScreener
Aquestive Therapeutics Stock Dips Amid Financial Challenges - StocksToTrade
Oklo, Applied Digital, Opendoor Technologies, Vistra, Aquestive Therapeutics: Stocks Making The Biggest Moves Today - Stocktwits
INVESTOR ALERT: Investigation of Aquestive Therapeutics, Inc. (AQST) by Holzer & Holzer, LLC - GlobeNewswire
Is Aquestive Therapeutics Inc. stock oversold or undervalued2025 Price Targets & Accurate Entry and Exit Point Alerts - ulpravda.ru
What's Going On With ARS Pharmaceuticals Stock Friday?ARS Pharmaceuticals (NASDAQ:SPRY) - Benzinga
INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Aquestive Therapeutics - 巴士的報
FDA Identifies NDA Deficiencies for Anaphylm as Review Continues, Aquestive Therapeutics Announces - Patient Care Online
BREAKING: Aquestive Therapeutics Investigated for Securities Fraud After FDA Identifies ... - Bluefield Daily Telegraph
BREAKING: Aquestive Therapeutics Investigated for Securities Fraud After FDA Identifies Deficiencies; Investors Should Contact Block & Leviton To Potentially Recover Losses - GlobeNewswire
Aquestive Therapeutics Faces Turbulent Market While Strategizing for Future Growth - timothysykes.com
FDA identifies deficiencies in Aquestive’s Anaphylm application By Investing.com - Investing.com Nigeria
FDA setback for Aquestive Thera’s Anaphylm - The Pharma Letter
Aquestive Therapeutics Stock (AQST) Opinions on FDA Deficiency Notice - Quiver Quantitative
Aquestive announces FDA identified deficiencies in NDA for Anaphylm - TipRanks
Why Is Aquestive Therapeutics Stock (AQST) Down Today? - TipRanks
Aquestive stock falls after FDA cites deficiencies in Anaphylm application By Investing.com - Investing.com South Africa
Aquestive stock falls after FDA cites deficiencies in Anaphylm application - Investing.com
Aquestive Faces FDA Deficiencies on Anaphylm NDA Review - TipRanks
Aquestive says FDA cited issues with Anaphylm (AQST:NASDAQ) - Seeking Alpha
Aquestive Therapeutics falls as FDA flags issues with oral allergy drug - TradingView — Track All Markets
Aquestive Therapeutics, Inc. Reports FDA Notice on Anaphylm NDA - TradingView — Track All Markets
Aquestive Therapeutics Announces Regulatory Development for Anaphylm™ (dibutepinephrine) Sublingual Film and Provides Business Update - The Manila Times
12 Health Care Stocks Moving In Friday's Pre-Market Session - Benzinga
Aquestive Therapeutics Announces Regulatory Development for - GlobeNewswire
Aquestive Therapeutics: Looking For The PDUFA Run-Up (NASDAQ:AQST) - Seeking Alpha
How risky is Aquestive Therapeutics Inc. stock nowJuly 2025 Summary & Risk Adjusted Buy and Sell Alerts - ulpravda.ru
Market Trends: How Aquestive Therapeutics Inc. stock benefits from tech adoptionDip Buying & Stepwise Entry and Exit Trade Signals - ulpravda.ru
Los Angeles Daily NewsAquestive Therapeutics, Inc.Common Stock (Nasdaq:AQST) Stock Quote - FinancialContent
Sentiment Review: How risky is Aquestive Therapeutics Inc. stock nowMarket Growth Report & Weekly Market Pulse Updates - ulpravda.ru
Published on: 2026-01-09 02:35:53 - ulpravda.ru
What catalysts could drive Aquestive Therapeutics Inc. stock higherSwing Trade & Risk Managed Investment Signals - ulpravda.ru
How Aquestive Therapeutics Inc. stock benefits from tech adoptionMarket Movement Recap & Real-Time Stock Entry Alerts - ulpravda.ru
Is Aquestive Therapeutics Inc. stock a smart buy before Fed meetingJuly 2025 WrapUp & Real-Time Market Trend Scan - ulpravda.ru
Aquestive Therapeutics, Inc.Common Stock (NQ: AQST - FinancialContent
Aquestive Therapeutics (AQST) Upgraded to Buy: Here's Why - sharewise.com
Why Aquestive Therapeutics Inc. stock could see breakout soonTrade Execution Strategies & Exceptional Profit Ideas - ulpravda.ru
Breakeven On The Horizon For Aquestive Therapeutics, Inc. (NASDAQ:AQST) - Yahoo Finance
Aquestive completes marketing application for Anaphylm in U.S. - MSN
Aquestive Therapeutics Stock Dips After-Hours On Q4 Miss — Retail Eyes Silver Linings - MSN
Aquestive Therapeutics, Inc. (NASDAQ:AQST) Receives Consensus Rating of "Buy" from Analysts - MarketBeat
Aquestive Therapeutics (NASDAQ:AQST) Shares Up 5.7%Should You Buy? - MarketBeat
Q1 2026 Preview: 5 FDA Decisions to Watch in Specialty Care - HCPLive
Aquestive Therapeutics, Inc.(NasdaqGM:AQST) added to S&P Pharmaceuticals Select Industry Index - marketscreener.com
Aquestive Therapeutics (NASDAQ:AQST) shareholders are still up 524% over 3 years despite pulling back 6.6% in the past week - simplywall.st
Is Aquestive Therapeutics Inc. stock gaining market shareWeekly Earnings Recap & Growth Focused Entry Point Reports - Улправда
Is Aquestive Therapeutics Inc. stock a buy on dips2025 Valuation Update & Entry Point Confirmation Signals - Улправда
0.37%
1.55%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):